ancialcontent.com/prnews?Page=Quote&Ticker=AEZS"> AEZS; TSX: AEZ) (the "Company"), earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer. The trial was conducted by the German AGO Study Group and centers in Bulgaria. The presentation was made by Prof. Günter Emons, Chairman, Department of Obstetrics & Gynaecology Georg-August University Göttingen, Germany during a poster session at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics currently being held in Berlin, Germany.
"The safety and efficacy of AEZS-108 in our study on advanced endometrial cancer was very encouraging," commented Prof. Günter Emons. "We must keep in mind that we used AEZS-108 as a single agent treatment only, and still achieved good rates of objective response and disease stabilization. Importantly from the patients' point of view, overall survival was similar to what has been reported with more aggressive and less well tolerated combination chemotherapy regimens."
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris added, "We would first like to thank Dr. Emons and all those involved in this trial for their dedicated work. These exciting positive results in endometrial cancer along with positive data for ovarian cancer disclosed earlier this year, reaffirm AEZS-108's potential as a novel targeted approach for the treatment of cancer. We now look forward to the further late-stage development of AEZS-108 for the benefit of women battling gynaecological cancers."
The poster (abstract #378) entitled, "Phase II study of AEZS-108, a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer", G. Emons, J. Sehouli, G. Gorchev, A. Hristamian, A. Staehle, LC. Hanker, P. Wimberger, M.W. Beckmann, V. Taskova, and C. Gruendker for the AGO Study Group, Germany, details the use of AEZS-10Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany2
. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results3
. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)4
. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-1085
. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 20106
. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 127
. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma8
. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer9
. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer10
. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering11
. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering